Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics

Nature Reviews Cardiology

Volumn 11, Issue 2, 2014, Pages 72-73

  Mikhailidis, Dimitri P ^a   Athyros, Vasilios G ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICRORNA; PLACEBO;

ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; FAMILY HISTORY; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SMOKING; SYSTOLIC BLOOD PRESSURE; TARGETED GENE REPAIR;

DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84893648929     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.209     Document Type: Review

References (9)

1. Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation http://dx.doi.org/10.1161/01.cir.0000437738. 63853.7a.
2. Desai, N. R. et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of NCEP ATP III LDL C goals among high risk patients: An analysis from the LAPLACE TIMI 57 trial. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.09.048
3. Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006
4. Desai, N. R. et al. AMG 145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy. Circulation 128, 962-969 (2013
5. Stein, E. A. et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128, 2113-2120 (2013
6. Koren, M. J. et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia. Circulation http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007012
7. McKenney, J. M. et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59, 2344-2353 (2012
8. Rotllan, N., Ramírez, C. M., Aryal, B., Esau, C. C. & Fernández-Hernando, C. Therapeutic silencing of microRNA 33 inhibits the progression of atherosclerosis in Ldlr-/- mice - brief report. Arterioscler. Thromb. Vasc. Biol. 33, 1973-1977 (2013
9. Eberlé, D. et al. Inducible Apoe gene repair in hypomorphic ApoE mice deficient in the low density lipoprotein receptor promotes atheroma stabilization with a human-like lipoprotein profile. Arterioscler. Thromb. Vasc. Biol. 33, 1759-1767 (2013